
Surge in Pediatric GLP-1 Prescriptions Raises Safety and Cost Concerns
Prescriptions for GLP-1 weight-loss drugs among children under 12 have surged 310 times since 2019, with over 20,000 young patients receiving these medications. While FDA-approved for ages 12 and older, off-label use is common for younger children. Experts warn that long-term safety data is lacking, and nearly 17% of young users developed nutritional deficiencies within a year. Insurance coverage remains inconsistent, and doctors emphasize screening for eating disorders before prescribing.












